Abstract
Treatment with glucagon-like peptide-1 analogues including liraglutide is a new treatment option for patients with type 2 diabetes. Treatment with liraglutide decreases HbA1c by 1-2%, and additionally liraglutide has a reducing effect on weight, lipids and blood pressure. Most adverse events are related to the gastrointestinal system and most often they disappear within a few weeks. The risk of major hypoglycaemic episodes is minimal. Long term data on treatment and adverse events with liraglutide are still lacking.
Bidragets oversatte titel | Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 173 |
Udgave nummer | 26 |
Sider (fra-til) | 1863-9 |
Antal sider | 7 |
ISSN | 0041-5782 |
Status | Udgivet - 27 jun. 2011 |
Emneord
- Blood Glucose
- Blood Pressure
- Body Weight
- Diabetes Mellitus, Type 2
- Drug Therapy, Combination
- Glucagon-Like Peptide 1
- Hemoglobin A, Glycosylated
- Humans
- Hypoglycemic Agents
- Lipids
- Treatment Outcome